Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15136112 | 1.00 | HTR2A (0.39) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL14706379 | 0.94 | KDM4E (0.41) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL15135714 | 0.94 | KDM4E (0.41) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL14575871 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL14575869 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL15171151 | 0.82 | LSS (0.40) | HTR2AHTR2CHTR2BSIGMAR1LSS | |
| SCHEMBL15156187 | 0.82 | PIK3CD (0.33) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL16340770 | 0.82 | PIK3CD (0.33) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL15156189 | 0.82 | PIK3CD (0.33) | HTR2AHTR2CHTR2BSIGMAR1KDM4E | |
| SCHEMBL15156191 | 0.82 | PIK3CD (0.33) | HTR2AHTR2CHTR2BSIGMAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400521-A1 | QUINAZOLINE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2024-12-05 | — | — | US | disclosed |
| WO-2023051687-A1 | QUINAZOLINE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-115894383-A | Quinazoline compound, composition and application thereof | 北京赛特明强医药科技有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2020-03-12 | — | — | US | disclosed |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2019-04-04 | — | — | US | disclosed |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-02-01 | — | — | US | disclosed |
| US-9862722-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2018-01-09 | — | — | US | disclosed |
| US-9656988-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS LLC (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| EP-3147285-A2 | PURINONE COMPOUNDS AS KINASE INHIBITORS | Pharmacyclics, Inc. (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20130197014-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197014-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197014-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| WO-2013102059-A1 | PYRAZOLO [3, 4-D] PYRIMIDINE AND PYRROLO [2, 3-D] PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | PHARMACYCLICS, INC. (US) | 2013-07-04 | — | — | WO | disclosed |
| US-8377946-B1 | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors | PHARMACYCLICS, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| WO-2013010136-A2 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | WO | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2013-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172314-A1 | PYRAZOLO[3,4-d]PYRIMIDINE AND PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, LYN | HTR2A 3635/4885HTR2C 2751/4885HTR2B 3099/4885 |
| US-20130018032-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | HTR2A 4474/4885HTR2C 3968/4885HTR2B 4154/4885 |
| US-20180030027-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2A 4019/4885HTR2C 3734/4885HTR2B 3298/4885 |
| US-20200079754-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LYN, LCK | HTR2A 4000/4885HTR2C 3942/4885HTR2B 3559/4885 |
| US-20240400521-A1 | QUINAZOLINE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | ERBB2, ABL1, EGFR | HTR2A 882/4885HTR2C 333/4885HTR2B 952/4885 |
| US-20190100505-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LYN, LCK | HTR2A 3909/4885HTR2C 3688/4885HTR2B 3267/4885 |
| US-20130197014-A1 | PURINONE COMPOUNDS AS KINASE INHIBITORS | BTK, LCK, BCL9 | HTR2A 1642/4885HTR2C 1616/4885HTR2B 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.